TAK-438 Placebo

DRUG5 trials

Sponsors

Takeda

Conditions

Dose Finding StudyDuodenal UlcerErosive Esophagitis(EE)Gastric UlcerGastroesophageal Reflux Disease (GERD)

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

CompletedNCT02123953

TakedaDose Finding Study

Start: 2008-10-31End: 2009-03-31Updated: 2014-04-28

Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects

CompletedNCT02141698

TakedaDose Finding Study

Start: 2007-10-31End: 2008-02-29Updated: 2014-05-19

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

CompletedNCT02141711

TakedaErosive Esophagitis(EE), Gastroesophageal Reflux Disease (GERD)

Start: 2008-10-31End: 2009-02-28Updated: 2014-05-19

Phase 3

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

CompletedNCT03050359

TakedaDuodenal Ulcer

Start: 2017-04-05End: 2019-07-19Updated: 2020-06-12

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

CompletedNCT03050307

TakedaGastric Ulcer

Start: 2017-04-17End: 2020-05-26Updated: 2021-06-18

Related Papers

Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials.

2024-01-014 citations

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.

2015-02-23237 citations